Brokerages Set Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Target Price at $12.62

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) have been given an average recommendation of “Buy” by the nine analysts that are covering the firm, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $12.6250.

CATX has been the topic of several recent research reports. Truist Financial set a $12.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, March 17th. B. Riley Financial boosted their price target on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, March 18th. BTIG Research restated a “buy” rating and issued a $14.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, March 17th. Royal Bank Of Canada reduced their price objective on shares of Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 17th. Finally, UBS Group lifted their target price on shares of Perspective Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, March 18th.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $3.63 on Monday. The business’s 50-day simple moving average is $3.56 and its 200 day simple moving average is $3.86. Perspective Therapeutics has a 12-month low of $1.96 and a 12-month high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The firm had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.16 million. Perspective Therapeutics had a negative return on equity of 42.33% and a negative net margin of 17,982.69%. Equities research analysts forecast that Perspective Therapeutics will post -1.11 EPS for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors have recently made changes to their positions in the stock. AXQ Capital LP increased its holdings in Perspective Therapeutics by 24.2% in the fourth quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after purchasing an additional 2,481 shares during the last quarter. Deutsche Bank AG boosted its holdings in Perspective Therapeutics by 6.1% during the fourth quarter. Deutsche Bank AG now owns 54,245 shares of the company’s stock worth $149,000 after buying an additional 3,119 shares during the last quarter. Vontobel Holding Ltd. boosted its holdings in Perspective Therapeutics by 25.0% during the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock worth $69,000 after buying an additional 5,000 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of Perspective Therapeutics by 184.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after buying an additional 5,475 shares during the period. Finally, Taylor & Morgan Wealth Management LLC grew its position in shares of Perspective Therapeutics by 6.6% during the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 97,000 shares of the company’s stock worth $267,000 after buying an additional 6,000 shares during the period. 54.66% of the stock is owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.